NICE recommends dabigatran as an option in thromboembolism

NICE has recommended that dabigatran etexilate (Pradaxa) should be considered as a possible treatment for adults with deep vein thrombosis (DVT) or pulmonary embolism (PE).

Dabigatran etexilate is rapidly absorbed and converted to its active form dabigatran, which inhibits both free and clot-bound thrombin
Dabigatran etexilate is rapidly absorbed and converted to its active form dabigatran, which inhibits both free and clot-bound thrombin
Dabigatran etexilate can be prescribed on the NHS for the treatment or for prevention of recurrent DVT and PE in adults.

The recommended dose of Boehringer Ingelheim's direct thrombin inhibitor in this indication is 150mg twice daily following treatment with a parenteral anticoagulant for at least five days. Treatment should be continued for at least three months based on transient risk factors (eg, recent surgery) or for longer in case of permanent risk factors or idiopathic DVT or PE.

The appraisal committee concluded that people welcome the choice of new oral anticoagulants such as dabigatran etexilate and rivaroxaban (Xarelto) because they avoid the need for the monitoring and dose adjustments associated with warfarin.

Pradaxa is also licensed for the primary prevention of venous thromboembolic events in adults who have undergone elective total hip or knee replacement surgery and for the prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation with one or more risk factors (eg, prior stroke or TIA, age ≥75 years, heart failure, diabetes or hypertension).

NICE has already published guidance approving the use of dabigatran etexilate in these indications - see TA157 (hip or knee replacement surgery) and TA249 (atrial fibrillation).

NICE guidance on dabigatran etexilate for the treatment and secondary prevention of DVT and/or PE

Follow MIMS on Twitter

Sign up for MIMS bulletins


Read these next

Eliquis approved for DVT and PE

Eliquis approved for DVT and PE

Eliquis (apixaban) is now licensed for the treatment...

Pradaxa now indicated for DVT and PE

Pradaxa now indicated for DVT and PE

Pradaxa (dabigatran) is now licensed for the treatment...

Pradaxa: safety update owing to risk of serious haemorrhage

Pradaxa: safety update owing to risk of serious haemorrhage

The MHRA has issued updated safety advice for the anticoagulant...

NICE approves dabigatran in atrial fibrillation

NICE approves dabigatran in atrial fibrillation

Dabigatran etexilate (Pradaxa) can now be prescribed...

Pradaxa: licence extended for use in patients with atrial fibrillation

Pradaxa: licence extended for use in patients with atrial fibrillation

Pradaxa (dabigatran) is now licensed for the prevention...


MIMS Clinics

Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases

Promo Image

Clinical calculators

Handy calculators and conversions for primary care.